Krystal Biotech Analysts Increase Their Forecasts Following Q4 Results
Portfolio Pulse from Avi Kapoor
Krystal Biotech, Inc. (NASDAQ:KRYS) exceeded Q4 expectations with earnings of 30 cents per share against an expected loss of 39 cents, and sales of $42.14 million over the $28.61 million forecast. The success follows the FDA approval and launch of VYJUVEK for dystrophic epidermolysis bullosa. The company anticipates FY24 R&D and SG&A expenses between $150 million to $175 million. Following the report, KRYS shares rose by 5.3% to $165.35. Guggenheim and Citigroup raised their price targets for KRYS to $175 and $195, respectively.
February 27, 2024 | 6:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Krystal Biotech surpassed Q4 earnings and sales forecasts, shares rose 5.3% following the report. Guggenheim and Citigroup raised their price targets to $175 and $195, respectively.
The positive earnings report and subsequent increase in price targets by reputable analysts like Guggenheim and Citigroup indicate a strong short-term bullish sentiment for KRYS. The successful launch of VYJUVEK and its contribution to the company's revenue further bolster investor confidence.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100